{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 65 of 92', 'CR845-CLIN3102', 'respect to the weekly mean of the daily 24-hour Worst Itching Intensity NRS', 'score >3 points will be calculated for each imputed dataset', 'Similar to the primary analysis, results of the logistic regression on the', 'multiply imputed data sets will be summarized by the SAS MIANALYZE', 'procedure.', 'Sensitivity 3: (Tipping point analysis', 'Multiple imputation with mixed missing data mechanisms (MNAR for a missing', 'data pattern and MAR for others) will be used to assess the robustness of the', 'MAR assumption. This sensitivity analysis is to investigate the departure from', 'MAR assumption by progressively decreasing the treatment differences with', 'respect to the NRS scores over the missing visits in active treatment group until', 'conclusion from the primary analysis is overturned. The MI procedure includes', 'the following steps:', 'Uses MCMC methodology from PROC MI by treatment group to impute the', 'intermittent missing data to a monotone missing pattern', 'Uses a standard MAR-based MI approach from PROC MI to impute data from', 'monotone missing data', 'For patients in the active treatment group, shift parameter from PROC MI will', 'be progressively applied to impute the missing data, until the p-value >0.05', 'To evaluate the potential impact of the IA on the properties of statistical inference at the', 'end of the trial, the primary and sensitivity analyses of the primary endpoint will also be', 'presented separately for the sample of patients enrolled into the study after the IA.', '8.7.2', 'Secondary Efficacy Enppoints', 'The secondary efficacy endpoints are the:', 'Change from baseline in itch-related quality of life at the end of Week 12 of the', 'Double-blind Treatment Period, as assessed by the 5-D Itch Scale total score;', 'Change from baseline in itch-related quality of life at the end of Week 12 of the', 'Double-blind Treatment Period, as assessed by the total Skindex-10 Scale total', 'core;', 'Proportion of patients achieving >4-point improvement from baseline with respect', 'to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 12', '(Day 79 to 85) of the Double-blind Treatment Period.', 'The 5-D Itch Scale and the Skindex-10 Scale score will be analyzed using a mixed effects', 'model with repeated measures (MMRM). The model will contain treatment, week, and', 'treatment-by-week interaction as fixed effects; baseline score, prior anti-itch medication', 'usage and presence of specific medical conditions as covariates; and patient as a random', 'effect. The baseline 5-D total score and the Skindex-10 total score will be defined as the', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 67 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 66 of 92', 'CR845-CLIN3102', 'value collected on Day 1, prior to randomization. Repeated measures will include values', 'collected at the end of Weeks 4, 8, 10, and 12 (end of treatment). The mean treatment', 'difference between CR845 0.5 mcg/kg and placebo will be estimated as the simple', 'contrast in the treatment effect at Double-blind Treatment Period Week 12.', 'It is important to note that, in HD patients, the study drug administered during the last', 'dialysis of a particular week is not cleared until the first dialysis of the next week.', 'Therefore, measurements that would reflect treatment effect at the end of a specific week', '(eg. Week 4) will actually be collected during the first day of the next week (eg, Week 5).', 'For the analysis of 5-D Itch Scale and the Skindex-1( Scale score, an appropriate', 'covariance matrix will be used to model the within-patient errors. The use of an', 'unstructured covariance matrix structure as well as other structures, such as spatial', 'patterns, that require fewer parameters (Toeplitz, autoregressive, or compound symmetry)', 'will be examined. The Akaike information criterion will be used to determine the', 'appropriate covariance matrix for the MMRM. The Kenward-Roger approximation will', 'be used to estimate the denominator degrees of freedom. Missing scores will not be', 'imputed. Assuming that the data are MAR, the estimates of the treatment differences', 'calculated from the MMRM described above are unbiased.', 'The proportion of patients achieving >4-point improvement from baseline with respect to', 'the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 12 of the', 'Double-blind Treatment Period will be analyzed following a methodology similar to the', 'one employed for the primary analysis of the primary endpoint.', '8.7.3', 'Hypothesis Testing Strategy', 'The efficacy of CR845 0.5 mcg/kg compared to placebo in pivotal Phase 3 study', 'CLIN3102 will be evaluated based on 1 primary and 3 secondary efficacy endpoints.', 'Testing of the primary efficacy endpoint will be 2-sided and conducted at the 5% error', 'level. The study will be considered positive if the null hypothesis of no treatment', 'difference in the primary efficacy analysis of the primary endpoint (proportion of patients', 'achieving >3-point improvement from baseline with respect to the Worst Itching Intensity', 'NRS) is rejected in favor of the alternative that patients randomized to CR845 experience', 'significantly less itching compared to patients randomized to placebo.', 'To protect the Type 1 error, a gate-keeping strategy will be implemented. Although the', 'p-values corresponding to the hypothesis testing of the secondary variables will be', 'reported, they will only be considered inferential if the primary analysis is statistically', 'significant. Testing of the 2 secondary efficacy endpoints will be performed sequentially', 'at a 2-sided 5% error level. The difference between CR845 0.5 mcg/kg and placebo with', 'respect to the 5-D Itch total score will be tested first. If results are statistically significant', 'in favor of CR845, testing with respect to the Skindex-10 total score will proceed and be', 'inferential.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 68 of 95']\n\n###\n\n", "completion": "END"}